-
Mashup Score: 0
The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Source: www.ajmc.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 0Tislelizumab Could Be a First-Line Treatment for HCC - 6 month(s) ago
Tislelizumab met its primary end point of overall survival and exceeded that of sorafenib in patients with unresectable hepatocellular carcinoma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Tislelizumab shows improved survival in unresectable liver cancer. https://t.co/h9QuuLJQDO https://t.co/N1C5fHz68l
-
-
Mashup Score: 0Tislelizumab Plus Chemotherapy Improves Overall Survival in ESCC - 11 month(s) ago
The phase 3 RATIONALE-306 study displayed encouraging survival and safety data among patients with advanced or metastatic esophageal squamous cell carcinoma who were treated with tislelizumab and chemotherapy.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
“The added effect of #tislelizumab to chemotherapy was shown in the patients with chemotherapy naïve advanced and recurred #ESCC." - Ken Kato, MD, PhD. #gicsm https://t.co/0jS0wP2LWX
-
-
Mashup Score: 1Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup - 1 year(s) ago
Tislelizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS vs. chemotherapy alone among patients with PD-L1-positive, advanced gastric or gastroesophageal junction adenocarcinoma.The findings, presented at ASCO Gastrointestinal Cancers Symposium, additionally showed first-line treatment with tislelizumab (BGB-A317, BeiGene), a humanized
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tislelizumab regimen new first-line option for gastric, gastroesophageal cancer subgroup. https://t.co/GY6N4TomXa #Tislelizumab #GastroesophagealCancer #cancer #GastricCancer @BeiGeneGlobal @ASCO
-
-
Mashup Score: 1
Better health-related quality of life outcomes were seen with tislelizumab vs sorafenib in patients with hepatocelluar carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Tislelizumab as frontline therapy for unresectable hepatocellular carcinoma had superior health-related quality of life outcomes vs sorafenib. #GI23 #gicsm #HCC | @dgsomucla https://t.co/HVyQRec0fu
-
-
Mashup Score: 0
Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC. Methods: The multireg
Source: www.karger.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Another global collaboration of @MSKCancerCenter @MSK_DeptOfMed @GABOUALFA @DucreuxMichel @LorenzaRimassa and more, of #tislelizumab for #HCC in Liver Cancer - https://t.co/O8qIJhzg3h @KargerPublisher. Thank you all for helping add options for dear patients!
-
-
Mashup Score: 0
At the 2022 ESMO Congress, results from the final analysis of the RATIONALE-301 study showed that tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs sorafenib in patients with unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results from the final analysis of the RATIONALE-301 study showed that #tislelizumab monotherapy continued to have clinically meaningful anti-tumor activity vs #sorafenib in patients with unresectable hepatocellular carcinoma. #HCC #lcsm https://t.co/H1HAxHUBOi https://t.co/KmKJulj2Qc
-
-
Mashup Score: 5
The phase 3 RATIONALE 301 trial of tislelizumab in patients with unresectable hepatocellular carcinoma has met its primary end point of non-inferior overall survival.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Tislelizumab met its primary end point of non-inferior overall survival compared with #sorafenib in the first-line in adult patients with unresectable hepatocellular carcinoma. #HCC https://t.co/JGrNI74uVF https://t.co/uzupaKxEep
-
-
Mashup Score: 0
Overall survival benefit was sustained with second- or third-line tislelizumab in patients with non–small cell lung cancer vs docetaxel in the final analysis of the phase 3 RATIONALE-303 trial.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Overall survival benefit was sustained with second- or third-line #tislelizumab in patients with non–small cell lung cancer vs #docetaxel in the final analysis of the phase 3 RATIONALE-303 trial. #lcsm #wclc22 https://t.co/QG9z1sae7t
-
-
Mashup Score: 4Exploring Tislelizumab for Unresectable HCC - 2 year(s) ago
Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ghassan K. Abou-Alfa, MD,discusses the phase 2 study of #tislelizumab in patients with unresectable hepatocellular carcinoma. #HCC @GABOUALFA @MSKCancerCenter https://t.co/0yaW0xfXWo
-
The FDA has approved #tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor. Learn more: https://t.co/OOyJ1R2cOY